EP1507793A4 - Neutrokine-alpha and neutrokine-alpha splice variant - Google Patents

Neutrokine-alpha and neutrokine-alpha splice variant

Info

Publication number
EP1507793A4
EP1507793A4 EP02786413A EP02786413A EP1507793A4 EP 1507793 A4 EP1507793 A4 EP 1507793A4 EP 02786413 A EP02786413 A EP 02786413A EP 02786413 A EP02786413 A EP 02786413A EP 1507793 A4 EP1507793 A4 EP 1507793A4
Authority
EP
European Patent Office
Prior art keywords
neutrokine
alpha
splice variant
variant
alpha splice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02786413A
Other languages
German (de)
French (fr)
Other versions
EP1507793A2 (en
Inventor
Guo-Liang Yu
Reinhard Ebner
Jian Ni
Craig A Rosen
Michael W Laird
Stephen Ullrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of EP1507793A2 publication Critical patent/EP1507793A2/en
Publication of EP1507793A4 publication Critical patent/EP1507793A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP02786413A 2001-10-17 2002-10-16 Neutrokine-alpha and neutrokine-alpha splice variant Withdrawn EP1507793A4 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US32950801P 2001-10-17 2001-10-17
US329508P 2001-10-17
US32974701P 2001-10-18 2001-10-18
US329747P 2001-10-18
US33083501P 2001-10-31 2001-10-31
US330835P 2001-10-31
US33147801P 2001-11-16 2001-11-16
US331478P 2001-11-16
US33672601P 2001-12-07 2001-12-07
US336726P 2001-12-07
US36854802P 2002-04-01 2002-04-01
US368548P 2002-04-01
PCT/US2002/032910 WO2003033658A2 (en) 2001-10-17 2002-10-16 Neutrokine-alpha and neutrokine-alpha splice variant

Publications (2)

Publication Number Publication Date
EP1507793A2 EP1507793A2 (en) 2005-02-23
EP1507793A4 true EP1507793A4 (en) 2006-02-01

Family

ID=27559746

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02786413A Withdrawn EP1507793A4 (en) 2001-10-17 2002-10-16 Neutrokine-alpha and neutrokine-alpha splice variant

Country Status (4)

Country Link
EP (1) EP1507793A4 (en)
AU (1) AU2002351495A1 (en)
CA (1) CA2476675A1 (en)
WO (1) WO2003033658A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173122B2 (en) 1996-10-25 2012-05-08 Human Genome Sciences, Inc. Methods of treatment using antibodies to neutrokine-alpha
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US9187548B2 (en) 2000-06-16 2015-11-17 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US20030091565A1 (en) 2000-08-18 2003-05-15 Beltzer James P. Binding polypeptides and methods based thereon
EP2332563A3 (en) 2004-10-13 2013-03-13 The Washington University Use of BAFF to treat sepsis
AU2006344395B2 (en) 2005-10-13 2013-05-02 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive diseases
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
AU2006318539B2 (en) 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
KR101328756B1 (en) 2006-05-30 2013-11-18 제넨테크, 인크. Antibodies and immunoconjugates and uses therefor
KR101241486B1 (en) 2007-10-30 2013-03-15 제넨테크, 인크. Antibody purification by cation exchange chromatography
WO2010019148A1 (en) 2008-08-14 2010-02-18 Genentech, Inc. Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography
JP5705115B2 (en) 2008-09-10 2015-04-22 ジェネンテック， インコーポレイテッド Compositions and methods for prevention of oxidative degradation of proteins
TR201905081T4 (en) 2010-03-22 2019-05-21 Hoffmann La Roche Compositions and methods useful for stabilizing protein-containing formulations.
BR112012027828A2 (en) 2010-05-03 2016-08-09 Genentech Inc matter composition, article of manufacture and method of reducing the viscosity of a protein containing formulation and preparing an aqueous protein containing formulation
WO2011163458A2 (en) 2010-06-24 2011-12-29 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
MY172426A (en) 2011-12-22 2019-11-25 Genentech Inc Ion exchange membrane chromatography
WO2020205716A1 (en) 2019-04-01 2020-10-08 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
CN110176272B (en) * 2019-04-18 2021-05-18 浙江工业大学 Protein disulfide bond prediction method based on multi-sequence association information

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018921A1 (en) * 1996-10-25 1998-05-07 Human Genome Sciences, Inc. NEUTROKINE $g(a)
WO2002018620A2 (en) * 2000-08-15 2002-03-07 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018921A1 (en) * 1996-10-25 1998-05-07 Human Genome Sciences, Inc. NEUTROKINE $g(a)
WO2002018620A2 (en) * 2000-08-15 2002-03-07 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEN B P ET AL: "Expression vectors for affinity purification and radiolabeling of proteins using Escherichia coli as host.", GENE. 11 FEB 1994, vol. 139, no. 1, 11 February 1994 (1994-02-11), pages 73 - 75, XP002356741, ISSN: 0378-1119 *
SCHALLER A ET AL: "Characterization of apxIVA, a new RTX determinant of Actinobacillus pleuropneumoniae.", MICROBIOLOGY (READING, ENGLAND) AUG 1999, vol. 145 ( Pt 8), August 1999 (1999-08-01), pages 2105 - 2116, XP002356740, ISSN: 1350-0872 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173122B2 (en) 1996-10-25 2012-05-08 Human Genome Sciences, Inc. Methods of treatment using antibodies to neutrokine-alpha
US8231873B2 (en) 1996-10-25 2012-07-31 Human Genome Sciences, Inc. Methods of treatment using antibodies to Neutrokine-alpha
US8303951B2 (en) 1996-10-25 2012-11-06 Human Genome Sciences, Inc. Neutrokine-alpha antibodies and methods of use thereof
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US9187548B2 (en) 2000-06-16 2015-11-17 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma

Also Published As

Publication number Publication date
WO2003033658A2 (en) 2003-04-24
WO2003033658A3 (en) 2004-05-27
AU2002351495A1 (en) 2003-04-28
CA2476675A1 (en) 2003-04-24
EP1507793A2 (en) 2005-02-23

Similar Documents

Publication Publication Date Title
EP1157110A4 (en) Neutrokine-alpha and neutrokine-alpha splice variant
EP1507793A4 (en) Neutrokine-alpha and neutrokine-alpha splice variant
EG23122A (en) Pyrrolcarboxamides and pyrrolcarbothioamides
EP1425162A4 (en) Optical materials and optical devices
AU9667901A (en) Mycoattractants and mycopesticides
EP1309718A4 (en) Neutrokine-alpha and neutrokine-alpha splice variant
EP1463742A4 (en) Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
AU2002234643A1 (en) Amphoteric liposomes and the use thereof
EP1408978A4 (en) Novel phenylamino-pyrimidines and uses thereof
IL154553A0 (en) Urocortin-iii and uses thereof
GB2376073B (en) Fluid-gauging systems and methods
AU2001292936A1 (en) Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
AU2001295185A1 (en) Multiplexing-interleaving and demultiplexing-deinterleaving
EP1392317A4 (en) Substituted 1-benzazepines and derivatives thereof
EP1408985A4 (en) Novel pyridopyrimidones and uses thereof
GB0224734D0 (en) Construction and elongate members therefor
GB0028589D0 (en) Optical devices and methods
EP1367123A4 (en) Neurotonin and use thereof
GB2365611B (en) Signs
AU2002354083A1 (en) Cylinder-lock and flat-key combination
HK1046707A1 (en) Neutrokine-alpha and neutrokine-alpha splice variant
AU2002354710A1 (en) Q9ul33/q9nzz4 and q9h5p3 splice variants
GB0129444D0 (en) Property marketing and conveyancy system
GB0213055D0 (en) Ground and ceiling advertisement unit
AU2002240498A1 (en) Protected deoxyadenosines and deoxyguanosines

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040517

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20051220

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060321